For the first time, we demonstrated that the inhibition of both PI3K/AKT activation and EMT progression with the combination of alpelisib and eribulin overcame paclitaxel resistance in endometrial cancer using our preclinical model. This evidence concerns the gene PIK3CA and endometrial cancer.